Delivering a Cost Effective, Practical and Robust Cell Therapy Supply Chain
FDA approvals for Novartis’ Kymriah™ and Kite’s Yescarta™ in 2017 ushered in a new era of medical treatments using cell and gene therapies. Transporting these high value, unique, and often irreplaceable autologous cells from point of collection, to processing center, and back to the patient for administration calls for a paradigm change to the traditional […]